In Stock Cell Lines
The CYP1A1 Knockout HK-2 Cell Line is a CRISPR/Cas9-edited human renal proximal tubule epithelial cell model exhibiting disrupted cytochrome P450 1A1 expression. It provides a defined loss-of-function system for exploring aryl hydrocarbon receptor (AHR)/ARNT-dependent transcriptional regulation and CYP1A1-driven metabolism of xenobiotics, procarcinogens, and steroid hormones. This knockout cell line is well-suited for nephrotoxicity screening, chemical carcinogenesis studies, and investigation of detoxification pathway dynamics. It supports functional assays such as EROD activity, benzo[a]pyrene viability testing, gene expression analysis, and DNA damage detection, enabling detailed mechanistic research in kidney-relevant toxicology and pharmacology.
ASCL4 Knockout HAP1 Polyclonal Cells
Cat. No. ARG21943
CNST Knockout K562 Polyclonal Cells
Cat. No. ARG19319
ERLIN2 Knockout A2780 Polyclonal Cells
Cat. No. ARG18472
ATXN1 Knockout 786-O Polyclonal Cells
Cat. No. ARG25044
AP4B1 Knockout A549 Polyclonal Cells
Cat. No. ARG31505
KSR1 Knockout jurkat Polyclonal Cells
Cat. No. ARG34437
The CYP1A1 Knockout HK-2 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human HK-2 proximal tubule epithelial cell line. This model features CRISPR/Cas9-mediated disruption of the CYP1A1 gene, resulting in loss of cytochrome P450 1A1 enzyme function. The knockout provides a stable and reproducible loss-of-function system for investigating the roles of CYP1A1 in xenobiotic metabolism and related signaling networks within a renal epithelial context.
The host cell line, HK-2, is an immortalized human proximal tubular epithelial line established from normal adult kidney cortex. These cells retain functional characteristics of proximal tubule epithelia, including roles in renal reabsorption and secretion, metabolic detoxification and synthesis, and endocrine functions. HK-2 cells are widely employed in nephrotoxicity screening and metabolic studies, and their human origin makes them a physiologically relevant platform for examining kidney-specific toxicological and metabolic pathways.
CYP1A1 encodes a monooxygenase that catalyzes the oxidation of diverse organic substrates, including xenobiotics, steroids, and procarcinogens. Transcription of CYP1A1 is tightly controlled by the aryl hydrocarbon receptor (AHR) signaling pathway. Upon ligand binding, AHR translocates to the nucleus with the AHR nuclear translocator (ARNT) and activates CYP1A1 expression. CYP1A1 enzymatic activity generates reactive intermediates that can induce DNA damage, oxidative stress, and aberrant estradiol hydroxylation. The enzyme operates in concert with NADPH-cytochrome P450 reductase (POR), cytochrome b5, and integrates into broader detoxification networks involving GST, UGT, and EPHX1. Additional upstream regulators include HIF1A, NRF2, and estrogen receptor, linking CYP1A1 to diverse cellular responses.
In the HK-2 proximal tubule background, knockout of CYP1A1 eliminates a key metabolic route for bioactivation of nephrotoxicants and procarcinogens. This enables dissection of renal-specific contributions to chemical carcinogenesis, steroid hormone processing, and AHR-mediated toxicity. The model is particularly valuable for studying kidney-relevant pathological processes associated with CYP1A1 dysfunction, such as cancer susceptibility and metabolic disorders, and for evaluating how loss of this enzyme alters the cellular response to environmental and therapeutic agents.
Researchers can apply the CYP1A1 Knockout HK-2 Cell Line in xenobiotic metabolism studies, chemical carcinogenesis research, drug toxicity testing, and AHR signaling pathway analysis. Typical assays include EROD activity measurement to confirm loss of CYP1A1 function, cell viability assays with benzo[a]pyrene to assess procarcinogen sensitivity, Western blotting and RT-qPCR for pathway markers, RNA-seq for transcriptomic profiling, and DNA damage assessments via Comet assay or immunofluorescence for ??-H2AX. For additional information or to discuss custom applications, please contact Ascent Research.